The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

June 21, 2018 • By Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In addition to getting individuals at risk for RA to participate, for RA prevention to work on a broader level, it will be critical to have the support of a wide range of stakeholders. These stakeholders include industry, which will need to develop trials, drugs and diagnostic tools that can be used in prevention; governmental agencies, which will support the trials and infrastructure development for prevention; insurance companies; and healthcare provider systems, which will also participate in delivery of prevention. Further, the field will require a host of biomedical researchers, including clinical, translational and basic scientists, trialists, epidemiologists, public health policy experts and health economists. Digital health and social media may be an important part of publicizing, identifying, monitoring and implementing prevention.

You Might Also Like
  • Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
Explore This Issue
June 2018

Where Clinicians Fit In

Notably, clinicians will be a crucial part of the implementation of prevention, especially in the early stages—now—because they are likely to be the first to identify individuals who can participate in prevention studies. Individuals may have been referred to a rheumatologist because of aches, pains and ACPA positivity in the absence of clear synovitis. The temptation may exist to just treat these individuals; however, rheumatologists should be aware that RA prevention studies may be recruiting near them and that these individuals can be referred to help provide an evidence basis for RA prevention.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Further, when prevention in RA and potentially other rheumatic diseases becomes more established, clinicians will be a critical part of delivering prevention to the population. Although RA is one of the first rheumatic diseases to be evaluated for prevention, other diseases, such as lupus and gout, that follow a similar model of development of biomarker abnormalities preceding clinically apparent disease may also be targeted with preventive efforts. Indeed, an intervention trial called SMILE (Study of Anti-Malarials in Incomplete Lupus) is underway to evaluate the effectiveness of hydroxychloroquine in preventing progression of disease in people at risk for lupus.30

In sum, multiple clinical trials are now underway that may soon lead to clinically actionable, paradigm-changing ways in how we approach RA, as well as other rheumatic diseases. These clinical trials will inform the biologic changes and natural history preceding the development of RA. If successful, these trials could provide an evidence basis for pharmacologic or lifestyle interventions for patients prior to the development of clinical synovitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There is potential for broad implementation of RA prevention, but more work needs to be done to understand the long-term potential benefits, harms and cost effectiveness of these strategies. This model informs other rheumatic diseases that follow a similar framework of biomarker abnormalities preceding clinical onset. Rheumatologists should be aware of these advances and consider contributing to research when they are able.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Rheumatoid Arthritis Tagged With: lifestyle, Metrics, risk assessment, Risk FactorsIssue: June 2018

You Might Also Like:
  • Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis
  • 2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • 2013 ACR/ARHP Annual Meeting: Genetic Research Yields Clues to Pathogenesis of Rheumatoid Arthritis, Psoriatic Arthritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.